The Consortium of Independent Immunology Clinics is grateful for the support from our corporate partners who are committed to improving the lives of patients around the world. It is the generosity of these sponsors that allows the CIIC and its members the opportunity to continue to participate in research that benefits PIDD patients.
2022 KEY NOTE SPEAKER – BLUEPRINT MEDICINES
PLATINUM LEVEL SPONSORS
Blueprint Medicines is working to advance a deep pipeline of precision therapies, designed to allow patients to live longer, healthier lives. Their approach combines our leading expertise in protein kinases with sound execution and an intense focus on discovery.
For more than 75 years, Grifols has worked to improve the health and well-being of people around the world. Grifols is a global healthcare company that produces essential plasma medicines for patients and provides hospitals, pharmacies, and healthcare professionals with the tools, information, and services they need to help them deliver expert medical care.
Pharming is a global, commercial stage biopharmaceutical company that develops innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs. Pharming’s lead product, RUCONEST® is the first and only plasma-free rhC1INH protein replacement therapy. It is approved for the treatment of acute hereditary angioedema, or HAE, attacks.
ADMA Biologics is an end-to-end commercial biopharmaceutical company. ADMA Biologics is committed to manufacturing, marketing and developing specialty plasma-derived products for the prevention and treatment of infectious diseases in the immune compromised and other patients at risk for infection.
CSL Behring is a global biotherapeutics leader driven by their promise to save lives. CSL Behring meets patients’ needs using the latest technologies to develop and deliver innovative therapies. The company offers the broadest range of products in the industry for treating coagulation disorders, primary immune deficiencies, hereditary angioedema, respiratory disease, and neurological disorders.
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, nearly all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic diseases, infectious diseases and rare diseases.
Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discovering and delivering life-transforming treatments, and guided by our commitment to patients, our people, and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines.
GOLD LEVEL SPONSORS
KalVista Pharmaceuticals is a company focused on the discovery, development and commercialization of oral, small molecule protease inhibitors as new treatments for diseases with significant unmet need. They have developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE). KalVista has an R&D team with an established track record in the pharmaceutical development of small molecule protease inhibitors, world-leading expertise in the role of plasma kallikrein in disease, and a management team with the capability to bring small molecules through the clinic to commercialization. Offices and labs are in Cambridge, MA, Salisbury, UK and Salt Lake City, UT.